Trials / Completed
CompletedNCT02880956
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 453 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-8E12 | ABBV-8E12 solution for IV infusion |
| DRUG | placebo for ABBV-8E12 | placebo solution for intravenous (IV) infusion |
Timeline
- Start date
- 2017-01-26
- Primary completion
- 2021-03-30
- Completion
- 2021-07-28
- First posted
- 2016-08-26
- Last updated
- 2022-08-26
- Results posted
- 2022-08-26
Locations
68 sites across 11 countries: United States, Australia, Belgium, Canada, Denmark, Finland, Italy, Netherlands, New Zealand, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02880956. Inclusion in this directory is not an endorsement.